Early-stage development of antibody–drug conjugates (ADCs) and other complex bioconjugates demands speed, clarity, and confidence. To keep preclinical and first-in-human programs on track, development teams need robust processes and reliable analytical insight established as early as possible.
This on-demand webinar introduces Lonza’s plate-based bioconjugation screening platform, designed to help teams rapidly evaluate conjugation conditions, assess developability, and understand process robustness using a miniaturized, data-rich approach that supports faster, better decision-making.
Through real-world examples of plate-based analytical methods developed by Lonza, the webinar highlights the value of synchronized analytical readouts within bioconjugation screening workflows. By generating immediate insight into reaction performance, these methods enable efficient iteration and early process optimization. Topics include accelerated drug-to-antibody ratio (DAR) determination and purity assessment.
Together, these integrated screening and analytics capabilities help de-risk early ADC and bioconjugate development, strengthen data-driven decisions, and support a smoother transition from preclinical development to GMP manufacturing.
Watch this webinar to learn how to:
- Accelerate bioconjugate and ADC process development using plate-based screening
- Implement fast, plate-based analytical methods to support robust bioconjugation workflows
- Leverage Lonza’s platform to support bioconjugate development from early discovery through GMP manufacturing
